EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant

Fabio Scarpa iD, Ilenia Azzena, Alessandra Ciccozzi, Marta Giovanetti iD, Chiara Locci, Marco Casu iD, Pier Luigi Fiori iD, Alessandra Borsetti iD, Eleonora Cella iD, Miriana Quaranta, Stefano Pascarella iD, Daria Sanna iD und 1 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241713573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Fabio Scarpa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FONDAZIONE DI SARDEGNA bando 2022-2023 for the Dipartimento di Scienze Biomediche - UNISS to Fabio Scarpa, FONDAZIONE DI SARDEGNA bando 2022-2023 for the Dipartimento di Scienze Biomediche - UNISS to Daria Sanna, PON "Ricerca e Innovazione" 2014-2020 to Marta Giovanetti.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The XBB.1.16 SARS-CoV-2 variant, also known as Arcturus, is a recent descendant lineage of the recombinant XBB (nicknamed Gryphon). Compared to its direct progenitor, XBB.1, XBB.1.16 carries additional spike mutations in key antigenic sites, potentially conferring an ability to evade the immune response compared to other circulating lineages. In this context, we conducted a comprehensive genome-based survey to gain a detailed understanding of the evolution and potential dangers of the XBB.1.16 variant, which became dominant in late June. Genetic data indicates that the XBB.1.16 variant exhibits an evolutionary background with limited diversification, unlike dangerous lineages known for rapid changes. The evolutionary rate of XBB.1.16, which amounts to 3.95 × 10−4 subs/site/year, is slightly slower than that of its direct progenitors, XBB and XBB.1.5, which have been circulating for several months. A Bayesian Skyline Plot reconstruction suggests that the peak of genetic variability was reached in early May 2023, and currently, it is in a plateau phase with a viral population size similar to the levels observed in early March. Structural analyses indicate that, overall, the XBB.1.16 variant does not possess structural characteristics markedly different from those of the parent lineages, and the theoretical affinity for ACE2 does not seem to change among the compared variants. In conclusion, the genetic and structural analyses of SARS-CoV-2 XBB.1.16 do not provide evidence of its exceptional danger or high expansion capability. Detected differences with previous lineages are probably due to genetic drift, which allows the virus constant adaptability to the host, but they are not necessarily connected to a greater danger. Nevertheless, continuous genome-based monitoring is essential for a better understanding of its descendants and other lineages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansBayes TheoremSARS-CoV-2Genetic Drift

Stichwörter der Autor:innen

XBB.1.16epidemiologygeneticsgenome-based surveymolecular evolutionphylodynamics

Autor:innen und Institutionen

  • Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.
  • Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy.
  • Unit of Medical Statistics and Molecular Epidemiology, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Instituto Rene Rachou Fundação Oswaldo Cruz, Belo Horizonte 30190-009, MG, Brazil.
  • Sciences and Technologies for Sustainable Development and One Health, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Azienza Ospedaliera Universitaria (AOU) Sassari, 07100 Sassari, Italy.

ORCID-Profile: Fabio Scarpa, Marta Giovanetti, Marco Casu, Pier Luigi Fiori, Alessandra Borsetti, Eleonora Cella, Stefano Pascarella, Daria Sanna, Massimo Ciccozzi

Förderung

  • FONDAZIONE DI SARDEGNA bando 2022-2023 for the Dipartimento di Scienze Biomediche - UNISS to Fabio Scarpa
  • FONDAZIONE DI SARDEGNA bando 2022-2023 for the Dipartimento di Scienze Biomediche - UNISS to Daria Sanna
  • PON "Ricerca e Innovazione" 2014-2020 to Marta Giovanetti
  • CRP- ICGEB RESEARCH GRANT 2020 Project CRP/BRA20-03 to Marta Giovanetti
  • Sapienza grant to Stafano Pascarella
  • FONDAZIONE DI SARDEGNA bando 2022–2023 for the Dipartimento di Scienze Biomediche—UNISS
  • Ricerca e Innovazione
  • CRP-ICGEB RESEARCH GRANT 2020 Project

Zitieren

APA

Scarpa, F., Azzena, I., Ciccozzi, A., Giovanetti, M., Locci, C., Casu, M., Fiori, P. L., Borsetti, A., Cella, E., Quaranta, M., Pascarella, S., Sanna, D., & Ciccozzi, M. (2023). Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713573

Vancouver

Scarpa F, Azzena I, Ciccozzi A, Giovanetti M, Locci C, Casu M, et al. Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241713573

BibTeX
@article{Scarpa2023,
  author = {Scarpa, Fabio and Azzena, Ilenia and Ciccozzi, Alessandra and Giovanetti, Marta and Locci, Chiara and Casu, Marco and Fiori, Pier Luigi and Borsetti, Alessandra and Cella, Eleonora and Quaranta, Miriana and Pascarella, Stefano and Sanna, Daria and Ciccozzi, Massimo},
  title = {Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241713573}
}
Kostenlos starten →